Fibrocell to begin Phase I/II trial of FCX-007 to treat RDEB

The US Food and Drug Administration (FDA) has given approval for Fibrocell Science to start a Phase I/II clinical trial of its orphan gene-therapy product candidate, FCX-007, to treat recessive dystrophic epidermolysis bullosa (RDEB) in adults.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news